Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas.

International journal of cancer - 1 Nov 2017

Cowell John K, Qin Haiyan, Hu Tianxiang, Wu Qing, Bhole Aaron, Ren Mingqiang

Abstract excerpt

Stem cell leukemia/lymphoma syndrome (SCLL) is driven by constitutive activation of chimeric FGFR1 kinases generated by chromosome translocations. We have shown that FGFR inhibitors significantly suppress leukemia and lymphoma development in vivo, and cell viability in vitro. Since resistance to targeted therapies is a major reason for relapse, we developed FGFR1-overexpressing mouse and human cell lines that are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Gene Expression Regulation, Leukemic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia

Share to Lymphoma

Share to Phenylurea Compounds

Share to Pyrazoles

Share to Quinolines

Share to Receptor, Fibroblast Growth Factor, Type 1

Source

Open in PubMed Open full text

Identifiers

PMID: 28646488
DOI: 10.1002/ijc.30848
PMCID: PMC5850950

Genes

FGFR1
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas.PMID 28646488Read ↗

Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities.Semantic proximity Read ↗

Downregulation of PUMA underlies resistance to FGFR1 inhibitors in the stem cell leukemia/lymphoma syndromeSemantic proximity Read ↗

Critical individual roles of the BCR and FGFR1 kinase domains in BCR‐FGFR1‐driven stem cell leukemia/lymphoma syndromeSemantic proximity Read ↗

Targeting FGFR1 to suppress leukemogenesis in syndromic and <i>de novo</i> AML in murine modelsSemantic proximity Read ↗

Src Activation Plays an Important Key Role in Lymphomagenesis Induced by FGFR1 Fusion KinasesSemantic proximity Read ↗

Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.Semantic proximity Read ↗

Distinct signaling programs associated with progression of FGFR1 driven leukemia in a mouse model of stem cell leukemia lymphoma syndromeSemantic proximity Read ↗

Loss of the BCR-FGFR1 GEF Domain Suppresses RHOA Activation and Enhances B-Lymphomagenesis in MiceSemantic proximity Read ↗

Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398.Semantic proximity Read ↗

A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemiaSemantic proximity Read ↗

Dysregulated signaling pathways in the development of CNTRL-FGFR1-induced myeloid and lymphoid malignancies associated with FGFR1 in human and mouse models.Semantic proximity Read ↗

Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.